Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Jun 08, 2021 7:00 PM - Jun 11, 2021 12:00 AM

(Central Europe Standard Time)

Future of Evidence and Smart Health Conference

Leveraging RWE to advance healthcare decision-making.

Session 6: Novel Digital End Points

Session Chair(s)

Cécile Mathilde Ollivier, MS

Cécile Mathilde Ollivier, MS

VP Global Affairs

Critical Path Institute, Netherlands

Solène  Thieffry, MSc

Solène Thieffry, MSc

Global RWE Policy Lead

UCB, Belgium

Most endpoints used in clinical trials are not necessarily patients-preferred nor easy to collect in routine care on the long term. Enhancing endpoints measurement continuously from clinical practice to real-word would facilitate better healthcare decision making for individual patients and population-level health. The aim of the session is to provide regulatory requirements and current use cases to develop novel digital endpoints that would help to bridge the gap in endpoints measurement across drug life cycle.

Speaker(s)

Lada  Leyens, PhD, MSc

Regulatory Perspective on Digital Endpoints

Lada Leyens, PhD, MSc

Takeda, Switzerland

Senior Director, EUCAN regulatory head GI

Babak  Boroojerdi, DrMed, MBA

Digital endpoints

Babak Boroojerdi, DrMed, MBA

UCB Biosciences, Germany

Global Program Physician, Rare Disease Organization

Marcus  Grobe-Einsler, DrMed

SARAhome - a new Clinical Tool for assessing Ataxia at home

Marcus Grobe-Einsler, DrMed

German Center for Neurodegenerative Diseases (DZNE), Germany

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.